Wondering if PT 141 is safe? Learn what research and FDA labeling say about bremelanotide, side effects, nasal spray risks, and who should avoid it.
PT-141 (bremelanotide) is considered safe when it is used exactly as directed as an FDA-approved prescription injection for premenopausal women with hypoactive sexual desire disorder. Unapproved versions — nasal sprays, pre-mixed liquids, and research chemical powders sold online — do not share that track record, because no regulator has verified their purity, strength, or dosing. People with uncontrolled high blood pressure, known heart disease, or a history of darkening skin patches should talk with a healthcare professional before using PT-141 at all.
What PT-141 Is and How It Is Approved
PT-141 is the research name for bremelanotide, a melanocortin receptor agonist that works in the central nervous system rather than by increasing blood flow. The FDA approved it in 2019 under the brand name Vyleesi as a subcutaneous injection given into the abdomen or thigh.
The approved label is narrow:
- Who: premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
- Dose: 1.75 mg injected under the skin
- Frequency: no more than one dose in 24 hours, and no more than eight doses per month
- Timing: at least 45 minutes before anticipated sexual activity
PT-141 is not FDA-approved for men, for postmenopausal women, or in any nasal, oral, or topical form. In the United States it is a prescription-only medication, and selling or buying it without a valid prescription is not legal.
PT-141 Safety: Side Effects, Blood Pressure, and Skin Changes
Most of what is known about PT-141 safety comes from the RECONNECT phase 3 trials and from post-approval reporting. Most side effects are uncomfortable rather than dangerous, but a few deserve attention.
| Side effect | How common | What to know |
|---|---|---|
| Nausea | Very common (roughly 40% in trials) | Usually mild to moderate; often strongest in the first hours after injection |
| Flushing | Common (roughly 20%) | Temporary warmth or redness in the face and chest |
| Headache | Common (roughly 11%) | Typically eases within hours |
| Injection site reactions | Common | Pain, bruising, or irritation where the needle was placed |
| Blood pressure increase | Measured in most users | Small, temporary rise in systolic and diastolic pressure |
| Focal melanosis | Rare but reported | Darkening of skin, gums, or breast tissue with repeated use |
Blood pressure is the safety issue that draws the most scrutiny. PT-141 causes a short-lived rise in blood pressure, and the prescribing information warns against using it in people with uncontrolled hypertension or known cardiovascular disease.
Focal melanosis is another reason to respect the dosing limits. Dark patches on the face, gums, or breasts have been reported with repeated use, and the discoloration does not always fade after the medication is stopped.
PT-141 is not a treatment for a medical cause of low desire, and it does not replace counseling, a medication review, or a workup for hormonal and psychological factors.
Is PT-141 Nasal Spray Safe? What Is Actually in It
If you are searching for is pt-141 nasal spray safe, the honest answer is that no one can confirm it, because no nasal bremelanotide product has ever been reviewed or approved by the FDA. Sprays sold under this name come from compounding pharmacies or research chemical vendors, and their contents vary from batch to batch.
Three problems come up repeatedly with unapproved nasal products:
- Unknown concentration. A spray labeled “1 mg per pump” may deliver far more or far less, which makes accurate dosing impossible.
- Purity and sterility. Products sold “for research use only” are not made under pharmaceutical sterility standards, and contamination has been documented in similar gray-market peptides.
- Unstudied absorption. How much bremelanotide crosses the nasal lining, and how quickly, has not been established in controlled human studies.
An unapproved nasal spray is not automatically dangerous, but its risk is unmeasured rather than proven low. Anyone considering it should treat the decision as experimental and discuss it with a healthcare professional first.
Dosage, Timing, and Off-Label Use
The FDA-approved pt-141 dosage for women is 1.75 mg injected subcutaneously, no more than once in 24 hours and no more than eight times per month. Taking it more often does not improve results and raises the odds of nausea, blood pressure changes, and skin discoloration.
A common question is how long does pt-141 last, and the answer depends on the route of administration. Injected bremelanotide has a half-life of about 2.7 hours, and most users describe the window of effect as lasting several hours, with side effects such as nausea fading first. Nasal and oral forms have no reliable timing data.
Interest in pt-141 for men is widespread, but the evidence is thinner. Small studies in men with erectile dysfunction showed modest effects, and no large trial has established a safe and effective dose for male use. Use in men is off-label, which means a prescriber carries responsibility for a dose that no regulator has reviewed.
Where to Buy PT-141 and Who Should Avoid It
The only legitimate source is a licensed pharmacy filling a prescription from a healthcare professional. Knowing where to buy pt-141 outside that channel usually means buying from a research chemical site that sells “not for human consumption” products, which are unregulated and frequently mislabeled.
Some people should avoid PT-141 unless a clinician clears them:
- Anyone with uncontrolled high blood pressure or known heart disease
- People taking medicines that raise blood pressure or interact with bremelanotide, including naltrexone
- Anyone who has had focal melanosis or unexplained skin darkening
- Pregnant or breastfeeding women, since safety has not been established
Bring any side effect to a healthcare professional, and report serious reactions to the FDA’s MedWatch program.
The Bottom Line on PT-141 Safety
PT-141 has a documented safety record as a prescription injection for one specific group of women, and a much weaker safety story everywhere else.
- PT-141 is FDA-approved only as the injectable Vyleesi for premenopausal women with HSDD.
- PT-141 nasal spray is not FDA-approved, and its strength, purity, and absorption are unverified.
- Use in men is off-label, with no established safe dose.
- Blood pressure changes, nausea, and focal melanosis are the main risks to monitor.
Frequently Asked Questions
Is PT-141 safe for men to use?
PT-141 is not FDA-approved for men, so any male use is off-label. Small studies suggest it may slightly help some men with erectile difficulties, but no large trial has established a safe, effective dose, and the same blood pressure, nausea, and skin-darkening risks apply. Talk with a healthcare professional before considering it.
Does PT-141 nasal spray carry the same risks as the injection?
No. The nasal spray is not FDA-approved, so its concentration, sterility, and absorption are unverified. The injection delivers a measured 1.75 mg dose that was studied in clinical trials, while nasal products sold online vary by batch and often come from research chemical vendors.
What are the most common side effects of PT-141?
Nausea is the most common side effect, reported by roughly 40% of trial participants, followed by flushing, headache, and injection site reactions. PT-141 also causes a temporary rise in blood pressure, and rare cases of focal melanosis, or darkening of the skin and gums, have been reported with repeated use.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.